July 6, 2026 · Gynecologic oncology reports · DOI: 10.1016/j.gore.2026.102155

Immune checkpoint inhibitor-induced encephalitis in endometrial carcinoma: Distinguishing immune from infectious causes

Listen to this summary

This case study investigates the challenge of distinguishing between immune checkpoint inhibitor (ICI)-induced encephalitis and infectious causes in a patient with advanced endometrial carcinoma. The authors detail a 68-year-old woman who developed encephalopathy after pembrolizumab treatment, initially misdiagnosed due to overlapping symptoms with infections. The findings underscore the importance of recognizing ICI-related neurological adverse events, particularly in the context of concurrent infections and endocrine disorders, to ensure timely and effective treatment.

Laasyapriya Sarva, Natalia Alston, Ava Delonais-Parker, Shannon M Grabosch

This is one of 33,000+ journals available on OSLR. Try it free for 14 days.

Free 14-day trial. 33,000+ journals. Cancel anytime.

14-day free trial. No commitment.

"Oslr has become part of my weekly routine on my day off. The clinical relevance of the summaries is outstanding — I'd rate it 9/10. Being able to consume research hands-free is a huge advantage for busy physicians."

Dr. Jennifer Thompson

Dr. Jennifer Thompson

Portland, OR

Stay current without falling behind

33,000+ journals. 3-minute audio summaries. Free for 14 days.

Download on the App StoreGet it on Google Play